Citation

Dadas A, Washington J, Diaz-Arrastia R, Janigro D. Neuropsychiatr. Dis. Treat. 2018; 14: 2989-3000.

Affiliation

Department of Physiology, Case Western Reserve University, Cleveland, OH, USA, djanigro@flocel.com.

Copyright

(Copyright © 2018, Dove Press)

DOI

10.2147/NDT.S125620

PMID

30510421

PMCID

PMC6231511

Abstract

Biomarkers can be broadly defined as qualitative or quantitative measurements that convey information on the physiopathological state of a subject at a certain time point or disease state. Biomarkers can indicate health, pathology, or response to treatment, including unwanted side effects. When used as outcomes in clinical trials, biomarkers act as surrogates or substitutes for clinically meaningful endpoints. Biomarkers of disease can be diagnostic (the identification of the nature and cause of a condition) or prognostic (predicting the likelihood of a person's survival or outcome of a disease). In addition, genetic biomarkers can be used to quantify the risk of developing a certain disease. In the specific case of traumatic brain injury, surrogate blood biomarkers of imaging can improve the standard of care and reduce the costs of diagnosis. In addition, a prognostic role for biomarkers has been suggested in the case of post-traumatic epilepsy. Given the extensive literature on clinical biomarkers, we will focus herein on biomarkers which are present in peripheral body fluids such as saliva and blood. In particular, blood biomarkers, such as glial fibrillary acidic protein and salivary/blood S100B, will be discussed together with the use of nucleic acids (eg, DNA) collected from peripheral cells.

Language: en

Keywords

blood-brain barrier; fluid biomarkers; mild traumatic brain injury; neuroimaging; peripheral markers; post-traumatic epilepsy